Inhibitors of cyclin-dependent kinase and cancer

Journal of Molecular Medicine

Volumn 73, Issue 10, 1995, Pages 509-514

  Biggs, J R ^a   Kraft, A S ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; ENZYME INHIBITOR;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE; CELL GROWTH; ENZYME ACTIVITY; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; REVIEW;

ANIMAL; CELL CYCLE; CELL DIVISION; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; HUMAN; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; ONCOGENES; PHOSPHORYLATION;

EID: 0028846176     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/BF00198902     Document Type: Article

References (58)

1. Ordering S phase and M phase in the cell cycle
2. Cyclins and cancer II: cyclin D and CDK inhibitors come of age
3. p15 INK4B is a potential effector of TGF induced cell cycle arrest
4. Growth suppression by p18, a p16 and p14-related CDK6 inhibitor, correlates with wildtype pRB function
5. TAN1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms
6. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4
7. Increase p16 levels correlate with pRb alterations in human urothelial cells
8. Reciprocal RB inactivation and p16 INK4 expression in primary lung cancers and cell lines
9. A cell cycle regulator potentially involved in genesis of many tumor types
10. Deletions of the cdk4 inhibitor gene in multiple human cancers
11. Rates of p16 (MTS1) mutations in primary tumors with 9p loss
12. Rates of p16 (MTS1) mutations in primary tumors with 9p loss
13. p16 gene in uncultured tumors
14. Stability of critical genetic lesions in human colorectal carcinoma xenografts
15. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma
16. Frequent somatic mutation of MTS1/CDK41 gene in esophagael squamous cell carcinoma
17. MTS1/CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma
18. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in nonsmall cell lung cancers
19. Deletion of p16 and p15 genes in brain tumors
20. Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization
21. Deletions and rearrangement of CDKN2 in lymphoid malignancy
22. Homozygous MST1 (p16INK4A) deletion in primary tumor cells of 163 leukemic patients
23. p16 gene homozygous deletions in acute lymphoblastic leukemia
24. Germline p16 mutations in familial melanoma
25. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
26. WAF1, a petential mediator of p53 tumor suppression
27. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases
28. p21 is a universal inhibitor of cyclin kinases
29. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
30. The p21 cyclin-dependent kinase inhibitor directly controls DNA replication via interaction with PCNA
31. WAF1/Cip1 is induced in p53-mediated G1 arrest and apoptosis
32. p53-dependent apoptosis modulates the cytotoxcity of anticancer agents
33. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts
34. Altered cell cycle regulation in the lens of HPV 16 E6 or E7 transgenic mice: Implications for tumor suppressor gene function in development
35. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens
36. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes
37. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation
38. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/Cip1
39. Induction of WAF1/Cip1 by a p53-independent pathway
40. Induction of p21 (WAF1/Cip1) during differentiation
41. Transforming growth factor 1 can induce Cip1/WAF1 expression independent of the p53 pathway in ovarian cancer cells
42. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD
43. p53-independent expression of p21 in muscle and other terminally differentiating cells
44. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitotogenic signals
45. Interleukin2-mediated elimination of the p27Kiplcyclin-dependent kinase inhibitor prevented by rapamycin
46. Inactivation of the p34cdc2-cyclinB complex by the human WEE1 tyrosine kinase
47. Human WEE1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr 15
48. Relationshipas between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard
49. G2 delay induced by nitrogen mustard in human cells affects cyclinA/cdk2 and cyclinB1/cdc2 kinase complexes differently
50. Phosphorylation and activation of human cdc25C by cdc2-cyclin B and its involvement in the self amplification of MPF at mitosis
51. Activation of the phosphatase activity of human cdc25A by cdk2-cyclinE dependent phosphorylation at the G1/S transition
52. Cdc25A is a novel phosphatase functioning early in the cell cycle
53. Cell cycle regulation of CDK2 activity by phosphorylation of Thr 160 and Tyr 15
54. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine 14 and tyrosine 15
55. The cdc2-related protein p4OM015 is the catalytic subunit of a protein kinase that can activate p33cdk2 and p34cdc2
56. CAK, the p34cdc2 activating kinase, contains a protein identical to or closely related to p40M015
57. Phosphorylation independent activation of human cyclin-dependent kinase 2 by cyclin A in vivo
58. Cdi1, a human G1 and S phase protein phosphatase that associates with cdk2